Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Rezo Therapeutics Inc.

Headquarters: San Francisco, CA, United States of America
Year Founded: 2022
Status: Private

BioCentury | Jul 18, 2024
Management Tracks

Rosenberg named CFO of BeiGene

Plus: CEO Barbier, SVP Burns leave Cassava, and updates from Rezo and Haya
BioCentury | Jul 16, 2024
Management Tracks

Nadir Mahmood returning to Nkarta

Plus: Perry Sternberg named CEO of Sydnexis, and updates from SFA, Alkeus and Optibrium
BioCentury | Apr 26, 2024
Finance

Venture report: Arch, Foresite $1B AI play Xaira starting with Baker lab’s de novo biologics 

Plus rounds for Rubedo, Flindr, Endeavor, SynOx and more
BioCentury | Dec 9, 2023
Discovery & Translation

Blood signature of organ aging; plus updates from Roche, Feldan, Rezo

BioCentury’s roundup of translational innovations
BioCentury | Sep 20, 2023
Management Tracks

Rezo names Nazir Mahmood CEO

Plus: Bendtsen named CEO of Orphazyme, and updates from Acadia, OM1 and BioPorto
BioCentury | Nov 18, 2022
Regulation

Nov. 17 Quick Takes: FDA approves Provention’s mAb to slow onset of diabetes

Plus: Rezo’s launch, deals by Regeneron-CytomX and Marinus-Tenacia, the end of a GSK-Immatics deal, and Tenaya’s funding
Items per page:
1 - 6 of 6